CELLECTIS (ALCLS.PA) Fundamental Analysis & Valuation

EPA:ALCLS • FR0010425595

3.16 EUR
-0.15 (-4.53%)
Last: Mar 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This ALCLS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall ALCLS gets a fundamental rating of 2 out of 10. We evaluated ALCLS against 75 industry peers in the Biotechnology industry. Both the profitability and financial health of ALCLS have multiple concerns. ALCLS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. ALCLS.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALCLS has reported negative net income.
  • ALCLS had a negative operating cash flow in the past year.
  • ALCLS had negative earnings in each of the past 5 years.
  • In the past 5 years ALCLS reported 4 times negative operating cash flow.
ALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFALCLS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • The Return On Assets of ALCLS (-28.25%) is comparable to the rest of the industry.
  • ALCLS has a Return On Equity (-102.97%) which is in line with its industry peers.
Industry RankSector Rank
ROA -28.25%
ROE -102.97%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ALCLS.PA Yearly ROA, ROE, ROICALCLS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • With a Gross Margin value of 3.66%, ALCLS is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
  • ALCLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCLS.PA Yearly Profit, Operating, Gross MarginsALCLS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ALCLS.PA Health Analysis

2.1 Basic Checks

  • ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALCLS has been increased compared to 1 year ago.
  • ALCLS has more shares outstanding than it did 5 years ago.
  • ALCLS has a better debt/assets ratio than last year.
ALCLS.PA Yearly Shares OutstandingALCLS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALCLS.PA Yearly Total Debt VS Total AssetsALCLS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • ALCLS has an Altman-Z score of -0.49. This is a bad value and indicates that ALCLS is not financially healthy and even has some risk of bankruptcy.
  • ALCLS has a Altman-Z score (-0.49) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.91 indicates that ALCLS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.91, ALCLS perfoms like the industry average, outperforming 45.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Altman-Z -0.49
ROIC/WACCN/A
WACC6.41%
ALCLS.PA Yearly LT Debt VS Equity VS FCFALCLS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • ALCLS has a Current Ratio of 1.38. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
  • ALCLS's Current ratio of 1.38 is on the low side compared to the rest of the industry. ALCLS is outperformed by 62.67% of its industry peers.
  • ALCLS has a Quick Ratio of 1.38. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.
  • ALCLS has a Quick ratio (1.38) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.38
ALCLS.PA Yearly Current Assets VS Current LiabilitesALCLS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ALCLS.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 70.80% over the past year.
  • The Revenue has grown by 154.92% in the past year. This is a very strong growth!
  • The Revenue has been growing by 16.44% on average over the past years. This is quite good.
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%

3.2 Future

  • Based on estimates for the next years, ALCLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -54.16% on average per year.
  • Based on estimates for the next years, ALCLS will show a very strong growth in Revenue. The Revenue will grow by 25.15% on average per year.
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALCLS.PA Yearly Revenue VS EstimatesALCLS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
ALCLS.PA Yearly EPS VS EstimatesALCLS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALCLS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALCLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCLS.PA Price Earnings VS Forward Price EarningsALCLS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCLS.PA Per share dataALCLS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A cheap valuation may be justified as ALCLS's earnings are expected to decrease with -54.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALCLS.PA Dividend Analysis

5.1 Amount

  • No dividends for ALCLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALCLS.PA Fundamentals: All Metrics, Ratios and Statistics

CELLECTIS

EPA:ALCLS (3/6/2026, 7:00:00 PM)

3.16

-0.15 (-4.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-11
Inst Owners15.56%
Inst Owner ChangeN/A
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap317.03M
Revenue(TTM)112.63M
Net Income(TTM)-99.99M
Analysts84.62
Price Target6.63 (109.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.93%
Min EPS beat(2)4.37%
Max EPS beat(2)25.48%
EPS beat(4)4
Avg EPS beat(4)48.46%
Min EPS beat(4)4.37%
Max EPS beat(4)145.69%
EPS beat(8)7
Avg EPS beat(8)30.86%
EPS beat(12)9
Avg EPS beat(12)22.27%
EPS beat(16)12
Avg EPS beat(16)21.56%
Revenue beat(2)1
Avg Revenue beat(2)21.17%
Min Revenue beat(2)-20.05%
Max Revenue beat(2)62.39%
Revenue beat(4)3
Avg Revenue beat(4)64.94%
Min Revenue beat(4)-20.05%
Max Revenue beat(4)161.56%
Revenue beat(8)5
Avg Revenue beat(8)33.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)15.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)50.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.94
P/FCF N/A
P/OCF N/A
P/B 3.79
P/tB 3.84
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.8
BVpS0.83
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.25%
ROE -102.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.66%
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.89%
Cap/Sales 3.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.38
Quick Ratio 1.38
Altman-Z -0.49
F-Score3
WACC6.41%
ROIC/WACCN/A
Cap/Depr(3y)12.8%
Cap/Depr(5y)139.39%
Cap/Sales(3y)9.66%
Cap/Sales(5y)33.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%
EBIT growth 1Y46.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.42%
EBIT Next 3Y-33.24%
EBIT Next 5Y-29.24%
FCF growth 1Y50.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.93%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTIS / ALCLS.PA FAQ

Can you provide the ChartMill fundamental rating for CELLECTIS?

ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA.


What is the valuation status of CELLECTIS (ALCLS.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS (ALCLS.PA). This can be considered as Overvalued.


What is the profitability of ALCLS stock?

CELLECTIS (ALCLS.PA) has a profitability rating of 1 / 10.


Can you provide the financial health for ALCLS stock?

The financial health rating of CELLECTIS (ALCLS.PA) is 2 / 10.


What is the expected EPS growth for CELLECTIS (ALCLS.PA) stock?

The Earnings per Share (EPS) of CELLECTIS (ALCLS.PA) is expected to decline by -166.15% in the next year.